Regenxbio (RGNX) Tops Q4 EPS by 12c

Regenxbio (NASDAQ: RGNX) reported Q4 EPS of ($1.01), $0.12 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $21.21 million versus the consensus estimate of $23.47 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• Regenxbio Inc. (RGNX) PT Raised to $32 at Baird
• S&P Global (SPGI) Declares $0.97 Quarterly Dividend; 1% Yield
• Rocket Lab launches U.S. Space Force mission in record 16 hours